GENEDRIVE PLC — Director's Dealing 2021

Oct 11, 2021

National Storage Mechanism | Additional information

RNS Number : 5776O

Genedrive PLC

11 October 2021

genedrive plc

("genedrive", the "Group" or the "Company")

Director's Shareholding

London, UK - 11 October 2021:  genedrive plc (LSE: GDR), the near patient molecular diagnostics company has been advised that as a result of an administrative error Dr. Ian Gilham, the Company's chairman, subscribed for 111,121 Open Offer Shares rather than 80,000 Open Offer Shares as was previously announced on 29 September 2021.  As a result, Dr. Ian Gilham holds 614,295 Ordinary Shares in the Company, representing 0.67% of the Company's issued share capital.  A corrected version of the PDMR notification form originally issued on 29 September 2021 is set out below, the only material change is to the number of Open Offer Shares subscribed for by Dr. Ian Gilham.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 10 September 2021.

For further information, please contact:

genedrive plc	+44 (0) 161 989 0245
David Budd (Chief Executive Officer) Matthew Fowler (Chief Financial Officer)
Peel Hunt LLP - Nominated Adviser & Joint Broker		+44 (0) 20 7148 8900
James Steel (Investment Banking)
finnCap Ltd - Joint Broker	+44 (0) 20 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Walbrook PR - Financial PR & IR Adviser	+44 (0) 20 7933 8780
Paul McManus / Anna Dunphy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1. 

Details of the person discharging managerial responsibilities / person closely associated

a. 

Name

1.   David Budd

2.    Matthew Fowler

3.    Dr. Ian Gilham

4.    Tom Lindsay

5.    Chris Yates

2.

Reason for the notification

a. 

Position/status

1.   Chief Executive Officer

2.   Chief Financial Officer

3.   Non-Executive Chairman

4.   Non-Executive Director

5.    Non-Executive Director

b. 

Initial notification

/Amendment

Amendment

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a. 

Name

genedrive plc

b. 

LEI

213800ZYODIRZ87Y4K14

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a. 

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary Shares of 1.5p each

GB00B1VKB244

b. 

Nature of the transaction

Purchase of new ordinary shares pursuant to an open offer which remains subject to Admission and other conditions

c. 

Price(s) and volume(s)

Price(s) 1.    25p 2.    25p 3.    25p 4.    25p 5.    25p	Volume(s) 1.   80,000 2.   40,000 3.   111,121 4.   60,000 5.   20,000

d. 

Aggregated information

·Aggregated volume

·Price

N/A

e. 

Date of the transaction

28 September 2021

f. 

Place of the transaction

London

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV and certain military biological targets. The Company released a high throughput SARS-CoV-2 assay in 2020, and has a point of care version of the SARS-Cov-2 test in development.  Antibiotic Induced Hearing Loss represents the Company's first targeting of the Genedrive® system into an emergency/urgent care environment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHMZMMGLGZGMZM